tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat - tiakis and Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH) Kiel, Germany, January 8, 2025 – tiakis Biotech AG, a clinical-stage biopharmaceutical company...

tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients -       Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...